Compare chemotherapy, chemoradiation, or surgery alone after esophageal surgery
Part of Cancer, Digestive system clinical trials.
This Phase 3 trial looks at the best next step after surgery for thoracic esophageal squamous cell cancer that has spread to nearby lymph nodes. It compares adding chemotherapy, adding chemoradiation (chemotherapy plus radiation), or not adding additional treatment right away, to see which approach works best and is safest.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be willing to join and sign an informed consent form.
- You already had curative surgery (tumor removed with clear margins, called R0) and pathology confirmed thoracic esophageal squamous cell cancer.
- Your cancer stage must match pN1-2 (with certain pT1b-3 and M0 features), meaning nearby lymph nodes are involved but no distant spread.
- You should have good basic health: performance status (WHO PS) score 0–1 and age 18–75.
- Your heart, liver, and kidney blood tests (done within 1 week before the next treatment) must meet study limits.
- You must not have had any anti-cancer treatment before surgery, and you must not have an allergy to the chemotherapy drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the best way to treat locally advanced squamous cell esophageal cancer: either chemoradiation followed by planned surgery, or monitoring with surgery only if needed. It may help you choose a strategy that controls the cancer while aiming to reduce unnecessary procedures.
This trial studies whether additional treatment before surgery can improve outcomes for patients with esophageal squamous cell carcinoma. It focuses on those who have already received initial therapy and are scheduled for surgery.
This trial tests a treatment plan that combines chemotherapy and immunotherapy before surgery, followed by radiation and immunotherapy after surgery for people with esophageal squamous cell cancer. It aims to see if this approach helps prevent the cancer from coming back.
This trial tests giving a combination of chemotherapy, radiation therapy, and an immunotherapy drug before surgery for a type of esophageal cancer (squamous cell). The goal is to see if this approach helps shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This study compares chemotherapy alone versus chemotherapy plus radiation given before surgery for locally advanced esophagus squamous cell cancer. The goal is to see which treatment helps more people have a successful operation and better cancer control.
This trial tests combining a type of immunotherapy (adebrelimab) with chemotherapy before surgery, for esophageal cancer that can be removed. The goal is to see if this combo helps shrink the tumor and improve outcomes.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.